Bolt Biotherapeutics, Inc. Stock Price, News & Analysis

Bolt Biotherapeutics (Nasdaq: BOLT) announced interim clinical data from its Phase 1/2 study of BDC-1001 at the ESMO I-O Congress 2021. The study involved 57 subjects with HER2-expressing solid tumors, showcasing a favorable safety profile and early signs of clinical activity. Notably, 13 of 40 evaluable subjects displayed clinical activity, with one maintaining a durable partial response for 52 weeks. The company plans to continue dose-escalation studies and initiate combination therapy with Opdivo® by year-end 2021, aiming for optimized drug exposure levels.

Bolt Biotherapeutics (BOLT) has announced the presentation of interim clinical data for BDC-1001 at the ESMO I-O Congress 2021, scheduled from December 8-11, 2021. This data includes insights from over 50 patients and highlights safety, tolerability, and early signs of clinical activity. The presentation will inform an ongoing Phase 1/2 study and support the initiation of a combination dose-escalation study with Opdivo by year-end. The poster will be accessible online starting December 6, 2021, at 12 p.m. CET, with a company conference call planned for the same date at 8:00 a.m. ET.

Bolt Biotherapeutics (Nasdaq: BOLT) announces the appointments of Brian O’Callaghan and Frank D. Lee to its Board of Directors, while Peter Moldt steps down. O’Callaghan brings 30 years of biopharmaceutical experience, crucial for advancing Bolt's immuno-oncology pipeline. Lee, with over 25 years in product development, enhances the company’s commercial strategy. CEO Randall Schatzman highlights the transformative year for Bolt, marked by its IPO and progress in clinical trials. The company focuses on developing immune-stimulating therapeutics targeting HER2-expressing tumors, with promising collaborations established.

Bolt Biotherapeutics, Inc. presented new preclinical data at the 2021 SITC Annual Meeting, highlighting the potential of its Boltbody™ ISAC candidates for cancer treatment. Key presentations included BDC-2034, targeting CEA, which showed promising tumor clearance and immune activation in CEA-expressing cancers. Additional data on a PD-L1-targeted ISAC demonstrated improved anti-tumor efficacy. The company also validated Dectin-2 as a novel target for reprogramming tumor-associated macrophages. Bolt aims to initiate clinical development of BDC-2034 in 2022.

Bolt Biotherapeutics (BOLT) reported Q3 2021 financial results, revealing a cash position of $290.5 million, expected to fund operations through 2023. The company is making progress in its BDC-1001 Phase 1/2 trial for HER2-expressing solid tumors, with interim data from over 50 patients to be presented at the ESMO Immuno-Oncology Congress in December. Collaboration revenue reached $0.8 million, while R&D expenses increased to $19.3 million. The loss from operations for Q3 was $23.5 million, compared to $12.4 million in the same period last year.

Bolt Biotherapeutics (Nasdaq: BOLT) announced that CEO Randall C. Schatzman, Ph.D., will participate in the Stifel 2021 Virtual Healthcare Conference on November 16, 2021, at 1:00 p.m. PT. The event includes a fireside chat and opportunities for investor meetings. A live webcast will be available on Bolt's website, with archived replays accessible for 30 days post-event. Bolt is focused on developing innovative immuno-oncology agents, particularly its lead candidate BDC-1001, targeting HER2-expressing solid tumors.

Bolt Biotherapeutics (Nasdaq: BOLT) announced three presentations at the 2021 SITC Annual Meeting in Washington, D.C., from Nov. 10-14. These presentations focus on assets in Bolt’s preclinical pipeline, featuring two immune-stimulating antibody conjugate (ISAC) candidates and an agonist antibody. The poster presentations will include:

• BDC-2034: CEA-targeting ISAC for solid tumors.
• Dectin-2: Aiming at tumor macrophage reprogramming.
• PD-L1-targeted ISAC: Enhancing anti-tumor efficacy in preclinical models.

Bolt Biotherapeutics (Nasdaq: BOLT) announced a clinical collaboration with Bristol Myers Squibb (NYSE: BMY) to investigate the combination of BDC-1001, a HER2-targeting immune-stimulating antibody conjugate, with Bristol's PD-1 inhibitor, Opdivo (nivolumab). The Phase 1/2 trial will explore safety and effectiveness in HER2-expressing solid tumors. Preliminary data presented at ASCO indicated promising results. Bristol will supply Opdivo for the trial, which is set to begin dose escalation later in 2021.

Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company, has announced their participation in four virtual investor conferences this September. Key events include presentations at the Citi’s 16th Annual BioPharma Virtual Conference on Sept. 8, the Wells Fargo Virtual Healthcare Conference on Sept. 9, a fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Sept. 13, and a presentation at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference on Sept. 30. Live and archived webcasts will be available on Bolt's website.